{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-026649","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.547388+00:00","generated_at":"2026-06-28T16:58:13.242144+00:00","sec_items":["1.01","2.01","9.01","3.02","4.01","5.03","5.01","5.02","5.06"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"SAB Biotherapeutics completes de-SPAC merger; OLD SAB valued at $300M","bullets":["OLD SAB equity value set at $300M; conversion rate $10.10 per share.","Holders of 8,030,289 BCYP shares redeemed for ~$81.1M at ~$10.10/share.","Approximately $21.9M released to Company upon closing; $13.1M escrowed with Radcliffe.","Post-merger shares outstanding: 43,474,779; additional 12M earnout shares tied to stock price milestones.","Board set at 7 members; CFO Russell Beyer gets new employment agreement ($300K base, stock options)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-026649","json":"https://secwatch.observer/filing/0001493152-21-026649.json","markdown":"https://secwatch.observer/filing/0001493152-21-026649.md","text":"https://secwatch.observer/filing/0001493152-21-026649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T16:58:13.242144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0aaee8f429","claim":"Jeffrey G. Spragens was appointed as Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"Jeffrey G. Spragens 79 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1fc68bfa9f","claim":"William Polvino was appointed as Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"William Polvino, MD 61 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5098346c87","claim":"Christine Hamilton was appointed as Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"Christine Hamilton, MBA 65 Class III Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"659ab90f60","claim":"Thomas Luke was appointed as Chief Medical Officer at SAB Biotherapeutics, Inc..","evidence_excerpt":"Thomas Luke, MD 59 Chief Medical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"6bc1aff19c","claim":"Samuel J. Reich was appointed as Executive Chairman at SAB Biotherapeutics, Inc..","evidence_excerpt":"Samuel J. Reich 46 Class III Director and Executive Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"7ec86f7d80","claim":"Samuel J. Reich departed as Executive Officer at SAB Biotherapeutics, Inc..","evidence_excerpt":"Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"96109cb8cf","claim":"Charles H. Randall, Jr. was appointed as Chief Strategy Officer at SAB Biotherapeutics, Inc..","evidence_excerpt":"Charles H. Randall, Jr., MBA 58 Chief Strategy Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Strategy Officer"}],"fact_type":"executive_change"},{"claim_id":"9d226fece6","claim":"Ilan Katz departed as Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a416b28d4d","claim":"Eddie J. Sullivan was appointed as President and Chief Executive Officer at SAB Biotherapeutics, Inc..","evidence_excerpt":"Eddie J. Sullivan, PhD 55 Class III Director, President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b87dc24555","claim":"David Link was appointed as Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"David Link 66 Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c5ce884dae","claim":"Mervyn Turner was appointed as Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"Mervyn Turner, PhD 74 Class I Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cd5bc26652","claim":"James Martin departed as Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d8732979fd","claim":"Russell Beyer was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..","evidence_excerpt":"Russell Beyer 66 Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ded37d3e59","claim":"Stephen D. Collins departed as Director at SAB Biotherapeutics, Inc..","evidence_excerpt":"Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}